Prevention of cardiovascular events with calcium channel blocker-based combination therapies in patients with hypertension

A randomized controlled trial

Masunori Matsuzaki, Toshio Ogihara, Seiji Umemoto, Hiromi Rakugi, Hiroaki Matsuoka, Kazuyuki Shimada, Keishi Abe, Norihiro Suzuki, Tanenao Eto, Jitsuo Higaki, Sadayoshi Ito, Akira Kamiya, Kenjiro Kikuchi, Hiromichi Suzuki, Chuwa Tei, Yasuo Ohashi, Takao Saruta

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

Objectives: Current guidelines recommend the use of multiple medications for hypertension. The present study was aimed at determining which combination was optimal to prevent cardiovascular events. Methods:We conducted a prospective, randomized, open-label, blinded-endpoint trial. Hypertensive outpatients aged between 40 and 85 years who did not achieve target blood pressure (BP<140/90mmHg) with calcium channel blocker (CCB) benidipine 4mg/day were randomly assigned to receive angiotensin receptor blocker (ARB), β-blocker, or thiazide diuretic in addition to benidipine. Results: Among a total of 3501 patients (1167, benidipine-ARB; 1166, benidipine-β-blocker; and 1168, benidipine-thiazide), 3293 patients (1110, 1089, and 1094, respectively) who received each combination treatment were included in the analysis. Median follow-up was 3.61 years. At the end of the treatment, 64.1, 66.9, and 66.0% of patients in the benidipine-ARB, benidipine-β-blocker, and benidipine-thiazide groups achieved target BP, respectively. The cardiovascular composite endpoint occurred in 41 (3.7%), 48 (4.4%), and 32 (2.9%) patients, respectively: the hazard ratio was 1.26 in the benidipine-ARB (P=0.3505) and 1.54 in the benidipine-β-blocker (P=0.0567) groups compared with the benidipine-thiazide group. The secondary analyses revealed that benidipine and thiazide diuretic significantly reduced the incidence of fatal or nonfatal strokes (P=0.0109) and benidipine and ARB significantly reduced new-onset diabetes (P=0.0240) compared with benidipine and β-blocker. All trial treatments were safe and well tolerated. Conclusion: CCB combined with ARB, β-blocker, or thiazide diuretic was similarly effective for the prevention of cardiovascular events and the achievement of target BP.

Original languageEnglish
Pages (from-to)1649-1659
Number of pages11
JournalJournal of Hypertension
Volume29
Issue number8
DOIs
Publication statusPublished - 2011 Aug
Externally publishedYes

Fingerprint

Calcium Channel Blockers
Randomized Controlled Trials
Hypertension
Angiotensin Receptor Antagonists
Thiazides
Sodium Chloride Symporter Inhibitors
Therapeutics
benidipine
Outpatients

Keywords

  • adrenergic β-antagonists
  • angiotensin antagonists
  • antihypertensive therapy/diuretics
  • calcium channel blockers
  • clinical trials
  • combination
  • drug therapy

ASJC Scopus subject areas

  • Internal Medicine
  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Prevention of cardiovascular events with calcium channel blocker-based combination therapies in patients with hypertension : A randomized controlled trial. / Matsuzaki, Masunori; Ogihara, Toshio; Umemoto, Seiji; Rakugi, Hiromi; Matsuoka, Hiroaki; Shimada, Kazuyuki; Abe, Keishi; Suzuki, Norihiro; Eto, Tanenao; Higaki, Jitsuo; Ito, Sadayoshi; Kamiya, Akira; Kikuchi, Kenjiro; Suzuki, Hiromichi; Tei, Chuwa; Ohashi, Yasuo; Saruta, Takao.

In: Journal of Hypertension, Vol. 29, No. 8, 08.2011, p. 1649-1659.

Research output: Contribution to journalArticle

Matsuzaki, M, Ogihara, T, Umemoto, S, Rakugi, H, Matsuoka, H, Shimada, K, Abe, K, Suzuki, N, Eto, T, Higaki, J, Ito, S, Kamiya, A, Kikuchi, K, Suzuki, H, Tei, C, Ohashi, Y & Saruta, T 2011, 'Prevention of cardiovascular events with calcium channel blocker-based combination therapies in patients with hypertension: A randomized controlled trial', Journal of Hypertension, vol. 29, no. 8, pp. 1649-1659. https://doi.org/10.1097/HJH.0b013e328348345d
Matsuzaki, Masunori ; Ogihara, Toshio ; Umemoto, Seiji ; Rakugi, Hiromi ; Matsuoka, Hiroaki ; Shimada, Kazuyuki ; Abe, Keishi ; Suzuki, Norihiro ; Eto, Tanenao ; Higaki, Jitsuo ; Ito, Sadayoshi ; Kamiya, Akira ; Kikuchi, Kenjiro ; Suzuki, Hiromichi ; Tei, Chuwa ; Ohashi, Yasuo ; Saruta, Takao. / Prevention of cardiovascular events with calcium channel blocker-based combination therapies in patients with hypertension : A randomized controlled trial. In: Journal of Hypertension. 2011 ; Vol. 29, No. 8. pp. 1649-1659.
@article{4c24b7e91db042cd8727d84911708d10,
title = "Prevention of cardiovascular events with calcium channel blocker-based combination therapies in patients with hypertension: A randomized controlled trial",
abstract = "Objectives: Current guidelines recommend the use of multiple medications for hypertension. The present study was aimed at determining which combination was optimal to prevent cardiovascular events. Methods:We conducted a prospective, randomized, open-label, blinded-endpoint trial. Hypertensive outpatients aged between 40 and 85 years who did not achieve target blood pressure (BP<140/90mmHg) with calcium channel blocker (CCB) benidipine 4mg/day were randomly assigned to receive angiotensin receptor blocker (ARB), β-blocker, or thiazide diuretic in addition to benidipine. Results: Among a total of 3501 patients (1167, benidipine-ARB; 1166, benidipine-β-blocker; and 1168, benidipine-thiazide), 3293 patients (1110, 1089, and 1094, respectively) who received each combination treatment were included in the analysis. Median follow-up was 3.61 years. At the end of the treatment, 64.1, 66.9, and 66.0{\%} of patients in the benidipine-ARB, benidipine-β-blocker, and benidipine-thiazide groups achieved target BP, respectively. The cardiovascular composite endpoint occurred in 41 (3.7{\%}), 48 (4.4{\%}), and 32 (2.9{\%}) patients, respectively: the hazard ratio was 1.26 in the benidipine-ARB (P=0.3505) and 1.54 in the benidipine-β-blocker (P=0.0567) groups compared with the benidipine-thiazide group. The secondary analyses revealed that benidipine and thiazide diuretic significantly reduced the incidence of fatal or nonfatal strokes (P=0.0109) and benidipine and ARB significantly reduced new-onset diabetes (P=0.0240) compared with benidipine and β-blocker. All trial treatments were safe and well tolerated. Conclusion: CCB combined with ARB, β-blocker, or thiazide diuretic was similarly effective for the prevention of cardiovascular events and the achievement of target BP.",
keywords = "adrenergic β-antagonists, angiotensin antagonists, antihypertensive therapy/diuretics, calcium channel blockers, clinical trials, combination, drug therapy",
author = "Masunori Matsuzaki and Toshio Ogihara and Seiji Umemoto and Hiromi Rakugi and Hiroaki Matsuoka and Kazuyuki Shimada and Keishi Abe and Norihiro Suzuki and Tanenao Eto and Jitsuo Higaki and Sadayoshi Ito and Akira Kamiya and Kenjiro Kikuchi and Hiromichi Suzuki and Chuwa Tei and Yasuo Ohashi and Takao Saruta",
year = "2011",
month = "8",
doi = "10.1097/HJH.0b013e328348345d",
language = "English",
volume = "29",
pages = "1649--1659",
journal = "Journal of Hypertension",
issn = "0263-6352",
publisher = "Lippincott Williams and Wilkins",
number = "8",

}

TY - JOUR

T1 - Prevention of cardiovascular events with calcium channel blocker-based combination therapies in patients with hypertension

T2 - A randomized controlled trial

AU - Matsuzaki, Masunori

AU - Ogihara, Toshio

AU - Umemoto, Seiji

AU - Rakugi, Hiromi

AU - Matsuoka, Hiroaki

AU - Shimada, Kazuyuki

AU - Abe, Keishi

AU - Suzuki, Norihiro

AU - Eto, Tanenao

AU - Higaki, Jitsuo

AU - Ito, Sadayoshi

AU - Kamiya, Akira

AU - Kikuchi, Kenjiro

AU - Suzuki, Hiromichi

AU - Tei, Chuwa

AU - Ohashi, Yasuo

AU - Saruta, Takao

PY - 2011/8

Y1 - 2011/8

N2 - Objectives: Current guidelines recommend the use of multiple medications for hypertension. The present study was aimed at determining which combination was optimal to prevent cardiovascular events. Methods:We conducted a prospective, randomized, open-label, blinded-endpoint trial. Hypertensive outpatients aged between 40 and 85 years who did not achieve target blood pressure (BP<140/90mmHg) with calcium channel blocker (CCB) benidipine 4mg/day were randomly assigned to receive angiotensin receptor blocker (ARB), β-blocker, or thiazide diuretic in addition to benidipine. Results: Among a total of 3501 patients (1167, benidipine-ARB; 1166, benidipine-β-blocker; and 1168, benidipine-thiazide), 3293 patients (1110, 1089, and 1094, respectively) who received each combination treatment were included in the analysis. Median follow-up was 3.61 years. At the end of the treatment, 64.1, 66.9, and 66.0% of patients in the benidipine-ARB, benidipine-β-blocker, and benidipine-thiazide groups achieved target BP, respectively. The cardiovascular composite endpoint occurred in 41 (3.7%), 48 (4.4%), and 32 (2.9%) patients, respectively: the hazard ratio was 1.26 in the benidipine-ARB (P=0.3505) and 1.54 in the benidipine-β-blocker (P=0.0567) groups compared with the benidipine-thiazide group. The secondary analyses revealed that benidipine and thiazide diuretic significantly reduced the incidence of fatal or nonfatal strokes (P=0.0109) and benidipine and ARB significantly reduced new-onset diabetes (P=0.0240) compared with benidipine and β-blocker. All trial treatments were safe and well tolerated. Conclusion: CCB combined with ARB, β-blocker, or thiazide diuretic was similarly effective for the prevention of cardiovascular events and the achievement of target BP.

AB - Objectives: Current guidelines recommend the use of multiple medications for hypertension. The present study was aimed at determining which combination was optimal to prevent cardiovascular events. Methods:We conducted a prospective, randomized, open-label, blinded-endpoint trial. Hypertensive outpatients aged between 40 and 85 years who did not achieve target blood pressure (BP<140/90mmHg) with calcium channel blocker (CCB) benidipine 4mg/day were randomly assigned to receive angiotensin receptor blocker (ARB), β-blocker, or thiazide diuretic in addition to benidipine. Results: Among a total of 3501 patients (1167, benidipine-ARB; 1166, benidipine-β-blocker; and 1168, benidipine-thiazide), 3293 patients (1110, 1089, and 1094, respectively) who received each combination treatment were included in the analysis. Median follow-up was 3.61 years. At the end of the treatment, 64.1, 66.9, and 66.0% of patients in the benidipine-ARB, benidipine-β-blocker, and benidipine-thiazide groups achieved target BP, respectively. The cardiovascular composite endpoint occurred in 41 (3.7%), 48 (4.4%), and 32 (2.9%) patients, respectively: the hazard ratio was 1.26 in the benidipine-ARB (P=0.3505) and 1.54 in the benidipine-β-blocker (P=0.0567) groups compared with the benidipine-thiazide group. The secondary analyses revealed that benidipine and thiazide diuretic significantly reduced the incidence of fatal or nonfatal strokes (P=0.0109) and benidipine and ARB significantly reduced new-onset diabetes (P=0.0240) compared with benidipine and β-blocker. All trial treatments were safe and well tolerated. Conclusion: CCB combined with ARB, β-blocker, or thiazide diuretic was similarly effective for the prevention of cardiovascular events and the achievement of target BP.

KW - adrenergic β-antagonists

KW - angiotensin antagonists

KW - antihypertensive therapy/diuretics

KW - calcium channel blockers

KW - clinical trials

KW - combination

KW - drug therapy

UR - http://www.scopus.com/inward/record.url?scp=79960591166&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960591166&partnerID=8YFLogxK

U2 - 10.1097/HJH.0b013e328348345d

DO - 10.1097/HJH.0b013e328348345d

M3 - Article

VL - 29

SP - 1649

EP - 1659

JO - Journal of Hypertension

JF - Journal of Hypertension

SN - 0263-6352

IS - 8

ER -